MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Aandelen Lijst・Insmed

Insmed

Gesloten

SectorGezondheidszorg

173.6 -0.25

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

172.54

Max

175.09

Belangrijke statistieken
By Trading Economics
Inkomsten	-48M -370M
Verkoop	35M 142M
Winstmarge	-259.952
Werknemers	1,271
EBITDA	-49M -344M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+25.83% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.7B 38B
Vorige openingsprijs	173.85
Vorige sluitingsprijs	173.6

Nieuwssentiment

By Acuity

100%

358 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

N/A / 69.2 Steun & Weerstand

Insmed Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 dec 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

10 jun 2025, 12:53 UTC

Belangrijke Marktbewegers

Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs

Peer Vergelijking

Prijswijziging

Insmed Prognose

Koersdoel

By TipRanks

25.83% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 219 USD 25.83%

Hoogste 263 USD

Laagste 158 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Insmed - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Insmed - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 69.2Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

358 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.